Synthesis of 4-(5-[18F]fluoromethyl-3-phenylisoxazol-4-yl) benzenesulfonamide, a new [18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 21, 2005, Pages 4699-4702

  Toyokuni, Tatsushi ^a   Kumar, J S Dileep ^a   Walsh, Joseph C ^a   Shapiro, Alan ^a   Talley, John J ^b   Phelps, Michael E ^a   Herschman, Harvey R ^a   Barrio, Jorge R ^a   Satyamurthy, Nagichettiar ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

Author keywords

COX 2; Fluorine 18; Inhibitor; PET; Radiotracer; Valdecoxib

Indexed keywords

4 (5 FLUOROMETHYL 3 PHENYLISOXAZOL 4 YL)BENZENESULFONAMIDE F 18; CYCLOOXYGENASE 2; FLUORIDE ION; RADIOPHARMACEUTICAL AGENT; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VALDECOXIB;

ARTICLE; DRUG SYNTHESIS; IMAGING; IMAGING SYSTEM; POSITRON EMISSION TOMOGRAPHY; QUANTUM YIELD; RADIOCHEMISTRY;

ANIMALS; CYCLOOXYGENASE INHIBITORS; FLUORINE RADIOISOTOPES; HUMANS; INHIBITORY CONCENTRATION 50; ISOXAZOLES; MACROPHAGES; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 25144508684     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.07.065     Document Type: Article

References (41)

1. H.R. Herschman Biochim. Biophys. Acta 1299 1996 125
2. M.E. Turini, and R.N. DuBois Annu. Rev. Med. 53 2002 35
3. D.L. Simmons, R.M. Botting, and T. Hla Pharmacol. Rev. 56 2004 387
4. Critical roles of COX-2 in the pathogenesis of Parkinson's disease and tumor angiogenesis have recently been identified. See: P. Teismann, K. Tieu, D. Choi, D. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, and S. Przedborski Proc. Natl. Acad. Sci. U.S.A. 100 2003 5473
5. S. Hunot, M. Vila, P. Teismann, R.J. Davis, E.C. Hirsch, S. Przedborski, P. Rakic, and R.A. Flavell Proc. Natl. Acad. Sci. U.S.A. 101 2004 665
6. S. Chang, C.H. Liu, R. Conway, D.K. Han, K. Nithipatikom, O.C. Trifan, T.F. Lane, and T. Hla Proc. Natl. Acad. Sci. U.S.A. 101 2004 591
7. J.J. Talley Prog. Med. Chem. 36 1999 201
8. A. Finckh, and M.D. Aronson Ann. Intern. Med. 142 2005 212
9. J.-M. Dogné, C.T. Supuran, and D. Pratico J. Med. Chem. 48 2005 2251
10. A black-box warning is the most serious type of warning in prescription drug labeling.
11. H.R. Herschman, J.J. Talley, and R. DuBois Mol. Imaging Biol. 5 2003 286
12. M.E. Phelps Proc. Natl. Acad. Sci. U.S.A. 97 2000 9226
13. J.S. Fowler, and A.P. Wolf Acc. Chem. Res. 30 1997 181
14. T.J. McCarthy, A.U. Sheriff, M.J. Graneto, J.J. Talley, and M.J. Welch J. Nucl. Med. 43 2002 117
15. Kumar, J. S. D.; Prabhakaran, J.; Parsey, R. V.; Underwood, M. D.; Simpson, N. R.; Majo, V. J.; van Heertum, R.; Mann, J. J. Abstract of Papers, 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, LA; Society of Nuclear medicine: VA, 2003; Abstract 1127.
16. Kumar, J. S. D.; Prabhakaran, J.; Underwood, M. D.; Parsey, R. V.; Arango, V.; Majo, V. J.; Simpson, N. R.; Arcement, J.; Cooper, A. R.; van Heertum, R. L.; Mann, J. J. Abstract of Papers, 226th National Meeting of the American Chemical Society, New York, NY; American Chemical Society: Washington, DC, 2003; Abstract MEDI 375.
17. 123I]iodinated analogue of celecoxib has also been synthesized for use with single photon emission computed tomography (SPECT). See: G.W. Kabalka, A.R. Mereddy, and H.M. Schuller J. Labelled Compd. Radiopharm. 48 2005 295
18. F.R. Wüst, A. Höhne, and P. Metz Org. Biomol. Chem. 3 2005 503
19. E.F.J. de Vries, A. van Waarde, A.R. Buursma, and W. Vaalburg J. Nucl. Med. 44 2003 1700
20. 11C]methylated analogue of the valdecoxib metabolite 5 has been reported. See: Kumar, J. S. D.; Prabhakaran, J.; Underwood, M. D.; Simpson, N. R.; Parsey, R. V.; Majo, V. J.; Arcement, J.; Arango, V.; van Heertum, R.; Mann, J. J. Abstract of Papers, 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, LA; Society of Nuclear Medicine: VA, 2003; Abstract 1110.
21. D. O'Hagan, and H.S. Rzepa Chem. Commun. 1997 645
22. J.K. Gierse, S.D. Hauser, D.P. Creeley, C. Koboldt, S.H. Rangwala, P.C. Isakson, and K. Seibert Biochem. J. 305 1995 479
23. S.T. Reddy, and H.R. Herschman J. Biol. Chem. 269 1994 15473
24. D.J. Wadleigh, S.T. Reddy, E. Kopp, S. Ghosh, and H.R. Herschman J. Biol. Chem. 275 2000 6259
25. +) 332.0631, found 332.0624.
26. +) 346.0780, found 346.0780.
27. J.J. Talley, D.L. Brown, J.S. Carter, M.J. Graneto, C.M. Koboldt, J.L. Masferrer, W.E. Perkins, R.S. Roger, A.F. Shaffer, Y.Y. Zhang, B.S. Zweifel, and K. Seibeert J. Med. Chem. 43 2000 775
28. Talley, J. J. U.S. Patent 5,859,257, 1999; Chem. Abstr. 1999, 130, 110269.
29. J.S.D. Kumar, M.M. Ho, J.M. Leung, and T. Toyokuni Adv. Synth. Catal. 344 2002 1146
30. +) 787.2148, found 787.2147.
31. +) 632.1981, found 632.1977.
32. f 0.45; hexanes-EtOAc 1:1 v/v). The total synthesis time was ∼120 min from EOB and the decay-corrected radiochemical yield was ∼40%. The specific activity was determined to be ∼2000 Ci/mmol at EOS based on the UV absorption and concentration standard curve.
33. The product was kept in EtOH until ready for use. For in vivo applications, the solution was diluted with normal saline such that the alcohol concentration was <5%.
34. 18F]fluoride stays at the origin. The non-radioactive 1 was stable in PBS (pH 7.4).
35. A PET scanner for small animals. See: A.F. Chatziioannou Eur. J. Nucl. Med. Mol. Imaging 29 2002 98
36. 18F (200-300 μCi in 200 μL saline containing <5% EtOH). Dynamic data acquisition commenced in a list mode at the time of injection to obtain a time-dependent organ distribution of radioactivity (frame times and sequence: 10 × 90 s and 21 × 300 s). The data were acquired in a 3-D mode with an axial span of ∼8 cm. The images were reconstructed using well-characterized 3-D filtered back-projection methods. The bony skeleton was visible in 15 min post-injection.
37. 18F (∼10 mCi) was followed by the data collection, as described in Ref. 27, except that a series of bed positions was used to cover the entire animal with each position (300-s frames) repeated 3-6 times. The bone structure became visible in 45 min post-injection.
38. J.J. Yuan, D.-C. Yang, J.Y. Zhang, R. Bible Jr., A. Karim, and J.W.A. Findlay Drug Metab. Dispos. 30 2002 1013
39. J.Y. Zhang, J.J. Yuan, Y.-F. Wang, R.H. Bible Jr., and A.P. Breau Drug Metab. Dispos. 31 2003 491 501
40. J.R. Barrio, N. Satyamurthy, S.-C. Huang, R.E. Keen, C.H.K. Nissenson, J.M. Hoffman, R.F. Ackermann, M.M. Bahn, J.C. Mazziotta, and M.E. Phelps J. Cerebral Blood Flow Metab. 9 1989 830
41. M.G. Stabin J. Nucl. Med. 37 1996 538